# EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis

> **NCT06646016** · PHASE2 · WITHDRAWN · sponsor: **Therakos LLC**

## Conditions studied

- Immune-related Colitis

## Interventions

- **DRUG:** Methoxsalen
- **DRUG:** Infliximab
- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT06646016
- **Lead sponsor:** Therakos LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-12-15
- **Primary completion:** 2026-02-06
- **Final completion:** 2027-02-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study Withdrawn by Sponsor prior to Enrollment.
- **Last updated:** 2025-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06646016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06646016, "EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06646016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*